



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
FEB 07 2003
TECH CENTER 1800/2900

In the Application of:
Dirk M. ANDERSON and
Laurent GALIBERT

Docket No.: 2852-E

Confirmation No. 4679

Serial No: 09/865,363

Group Art Unit: 1646

Filed: May 25, 2001

Examiner: O'Hara E.B.

For: ANTIBODIES AGAINST LIGAND FOR RECEPTOR ACTIVATOR OF NF- κ B

10/8
M.G.J
2/11/03

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
Washington, DC 20231

In response to the Examiner's Action dated 9/26/2002 (Paper No. 6), please enter the following amendments into the application:

In the Specification:

At page 1, please delete in its entirety the first paragraph immediately following the title, and substitute therefor the following paragraph:

B¹
-- This application is a divisional of USSN 09/577,780, filed May 24, 2000, now U.S. Patent No. 6,419,929, which is a divisional of USSN 08/995,659, filed December 22, 1997, now U.S. Patent No. 6,242,213, which claims the benefit of USSN 60/064,671, filed October 14, 1997, USSN 60/077,181, filed March 7, 1997 (filed originally as USSN 08/813,509), and USSN 60/059,978, filed December 23, 1996 (filed originally as USSN 08/772,330).--

At page 2, please delete in its entirety the paragraph beginning at line 35.

At page 3, please delete in its entirety the paragraph beginning at line 4, and substitute therefor the following paragraph:

B²
-- Figure 2 demonstrates that RANKL enhances DC allo-stimulatory capacity. Allogeneic T cells were incubated with varying numbers of irradiated DC cultured as described in Example 13. The cultures were pulsed with [³H]-thymidine and the cells harvested onto glass fiber sheets for counting. Values represent the mean \pm standard deviation (SD) of triplicate cultures.--

01/30/2003 BABRAHA1 00000095 090089 09865363

02 FC:1051 130.00 CH